1. Home
  2. MUA vs ANL Comparison

MUA vs ANL Comparison

Compare MUA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackrock MuniAssets Fund Inc

MUA

Blackrock MuniAssets Fund Inc

HOLD

Current Price

$10.93

Market Cap

537.8M

Sector

Finance

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$10.09

Market Cap

611.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MUA
ANL
Founded
N/A
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
537.8M
611.1M
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
MUA
ANL
Price
$10.93
$10.09
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$20.00
AVG Volume (30 Days)
112.4K
176.5K
Earning Date
01-01-0001
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$36.02
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.02
$0.88
52 Week High
$11.78
$17.25

Technical Indicators

Market Signals
Indicator
MUA
ANL
Relative Strength Index (RSI) 58.76 44.82
Support Level $10.50 $9.00
Resistance Level $11.11 $9.98
Average True Range (ATR) 0.10 1.41
MACD 0.01 0.03
Stochastic Oscillator 67.31 40.46

Price Performance

Historical Comparison
MUA
ANL

About MUA Blackrock MuniAssets Fund Inc

Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations. The Fund invests more of its total assets in municipal bonds.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: